BC018101 Activators
BC018101 activators encompass a diverse array of chemical compounds that, through distinct pathways, contribute to the functional activity augmentation of BC018101. Forskolin and IBMX enhance the protein's activity by increasing cAMP levels, leading to PKA activation. If BC018101 possesses PKA phosphorylation sites, these compounds would enhance its activity. Similarly, by inhibiting competing kinases, Epigallocatechin gallate could facilitate more active BC018101 pathways. PMA, acting as a PKC activator, and LY294002, inhibiting the PI3K/AKT pathway, could modify signaling cascades that intersect with the regulation of BC018101. U0126 and SB203580, by inhibiting MEK1/2 and p38 MAPK, respectively, may also shift the intracellular signaling equilibrium to favor pathways that upregulate BC018101 if it is responsive to these kinases.
In additionto acting on kinases, BC018101's activity can be modulated by lipid and calcium signaling molecules. Sphingosine-1-phosphate may indirectly activate BC018101 by engaging specific S1P receptor-mediated pathways, while A23187 (Calcimycin) and Thapsigargin, both influencing intracellular calcium levels, can potentiate the protein's activity if it is regulated by calcium-dependent mechanisms. Additionally, Zaprinast, through PDE5 inhibition and subsequent cGMP pathway activation, and Anisomycin, by inducing stress-activated protein kinases, could both serve to indirectly enhance the activity of BC018101. Collectively, these chemical activators operate through various signaling pathways to support the functional enhancement of BC018101, each having the potential to impact the protein's activity by leveraging unique aspects of cellular signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases which breaks down cAMP. By preventing cAMP degradation, IBMX indirectly maintains PKA activation, potentially enhancing BC018101 activity if it is regulated by PKA-mediated phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that might reduce competitive signaling, thereby potentially allowing the pathways that activate BC018101 to be more active if BC018101 is regulated by such competitive pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator. By activating PKC, PMA can modulate signaling pathways that lead to the activation of BC018101, assuming BC018101 is part of a PKC-dependent signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate downstream signaling, including AKT. If BC018101 activity is enhanced by AKT inhibition, LY294002 may indirectly enhance BC018101 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, part of the MAPK pathway. By inhibiting MEK1/2, U0126 may shift signaling toward pathways that activate BC018101, assuming BC018101 is enhanced by alternative pathway activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a lipid signaling molecule that can activate S1P receptors and downstream signaling pathways. If BC018101 is influenced by such pathways, S1P might enhance BC018101 activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore, which increases intracellular calcium levels. Elevated calcium can activate calcium-dependent proteins and pathways, potentially enhancing the activity of BC018101 if it is calcium-dependent. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of PDE5, leading to increased cGMP levels. If BC018101 is part of cGMP-dependent pathways, Zaprinast could indirectly enhance its activity through these pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases (SAPKs). If BC018101 activity is upregulated by SAPK activation, anisomycin may indirectly enhance BC018101 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 may relieve negative feedback loops or redirect signaling to pathways that upregulate BC018101 activity, assuming p38 has a regulatory role over BC018101. | ||||||